IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-02464775.html
   My bibliography  Save this paper

Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation

Author

Listed:
  • Philippe Grandjean

    (Harvard T.H. Chan School of Public Health)

  • Martine Bellanger

    (EA MOS - EA Management des Organisations de Santé - EHESP - École des Hautes Études en Santé Publique [EHESP] - PRES Sorbonne Paris Cité, EHESP - École des Hautes Études en Santé Publique [EHESP], SHS - Département des sciences humaines et sociales - EHESP - École des Hautes Études en Santé Publique [EHESP])

Abstract

Calculation of costs and the Burden of Disease (BoD) is useful in developing resource allocation and prioritization strategies in public and environmental health. While useful, the Disability-Adjusted Life Year (DALY) metric disregards subclinical dysfunctions, adheres to stringent causal criteria, and is hampered by gaps in environmental exposure data, especially from industrializing countries. For these reasons, a recently calculated environmental BoD of 5.18% of the total DALYs is likely underestimated. We combined and extended cost calculations for exposures to environmental chemicals, including neurotoxicants, air pollution, and endocrine disrupting chemicals, where sufficient data were available to determine dose-dependent adverse effects. Environmental exposure information allowed cost estimates for the U.S. and the EU, for OECD countries, though less comprehensive for industrializing countries. As a complement to these health economic estimations, we used attributable risk valuations from expert elicitations to as a third approach to assessing the environmental BoD. For comparison of the different estimates, we used country-specific monetary values of each DALY. The main limitation of DALY calculations is that they are available for few environmental chemicals and primarily based on mortality and impact and duration of clinical morbidity, while less serious conditions are mostly disregarded. Our economic estimates based on available exposure information and dose-response data on environmental risk factors need to be seen in conjunction with other assessments of the total cost for these environmental risk factors, as our estimate overlaps only slightly with the previously estimated environmental DALY costs and crude calculations relying on attributable risks for environmental risk factors. The three approaches complement one another and suggest that environmental chemical exposures contribute costs that may exceed 10% of the global domestic product and that current DALY calculations substantially underestimate the economic costs associated with preventable environmental risk factors. By including toxicological and epidemiological information and data on exposure distributions, more representative results can be obtained from utilizing health economic analyses of the adverse effects associated with environmental chemicals.

Suggested Citation

  • Philippe Grandjean & Martine Bellanger, 2017. "Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation," Post-Print hal-02464775, HAL.
  • Handle: RePEc:hal:journl:hal-02464775
    DOI: 10.1186/s12940-017-0340-3
    Note: View the original document on HAL open archive server: https://ehesp.hal.science/hal-02464775v1
    as

    Download full text from publisher

    File URL: https://ehesp.hal.science/hal-02464775v1/document
    Download Restriction: no

    File URL: https://libkey.io/10.1186/s12940-017-0340-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Gwinn, M.R. & Axelrad, D.A. & Bahadori, T. & Bussard, D. & Cascio, W.E. & Deener, K. & Dix, D. & Thomas, R.S. & Kavlock, R.J. & Burke, T.A., 2017. "Chemical risk assessment: Traditional vs public health perspectives," American Journal of Public Health, American Public Health Association, vol. 107(7), pages 1032-1039.
    2. Rabl,Ari & Spadaro,Joseph V. & Holland,Mike, 2014. "How Much Is Clean Air Worth?," Cambridge Books, Cambridge University Press, number 9781107043138, June.
    3. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Amal K. Mitra & Marinelle Payton & Nusrat Kabir & April Whitehead & Kimberly N. Ragland & Alexis Brown, 2020. "Potential Years of Life Lost Due to COVID-19 in the United States, Italy, and Germany: An Old Formula with Newer Ideas," IJERPH, MDPI, vol. 17(12), pages 1-9, June.
    2. Leonardo Barcellos de Bakker & Pedro Gasparinetti & Júlia Mello de Queiroz & Ana Claudia Santiago de Vasconcellos, 2021. "Economic Impacts on Human Health Resulting from the Use of Mercury in the Illegal Gold Mining in the Brazilian Amazon: A Methodological Assessment," IJERPH, MDPI, vol. 18(22), pages 1-26, November.
    3. Arlene Gabriela & Sarah Leong & Philip S. W. Ong & Derek Weinert & Joe Hlubucek & Peter W. Tait, 2022. "Strengthening Australia’s Chemical Regulation," IJERPH, MDPI, vol. 19(11), pages 1-24, May.
    4. Katarzyna Kordas & Julia Ravenscroft & Ying Cao & Elena V. McLean, 2018. "Lead Exposure in Low and Middle-Income Countries: Perspectives and Lessons on Patterns, Injustices, Economics, and Politics," IJERPH, MDPI, vol. 15(11), pages 1-18, October.
    5. Terence J. Centner, 2021. "Pesticide Usage Is Compromising People’s Health in the United States: Ideas for Reducing Damages," Agriculture, MDPI, vol. 11(6), pages 1-12, May.
    6. Antonio Belmonte & Pilar Muñoz & Juan Santos-Echeandía & Diego Romero, 2021. "Tissue Distribution of Mercury and Its Relationship with Selenium in Atlantic Bluefin Tuna ( Thunnus thynnus L.)," IJERPH, MDPI, vol. 18(24), pages 1-16, December.
    7. Daniel Slunge & Francisco Alpizar, 2019. "Market-Based Instruments for Managing Hazardous Chemicals: A Review of the Literature and Future Research Agenda," Sustainability, MDPI, vol. 11(16), pages 1-20, August.
    8. Herrera-Araujo, Daniel & Hammitt, James K. & Rheinberger, Christoph M., 2020. "Theoretical bounds on the value of improved health," Journal of Health Economics, Elsevier, vol. 72(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    2. Aidan Hollis, 2016. "Sustainable Financing of Innovative Therapies: A Review of Approaches," PharmacoEconomics, Springer, vol. 34(10), pages 971-980, October.
    3. Brand, Christian, 2016. "Beyond ‘Dieselgate’: Implications of unaccounted and future air pollutant emissions and energy use for cars in the United Kingdom," Energy Policy, Elsevier, vol. 97(C), pages 1-12.
    4. Byrne, Dominic & Kwak, Do Won & Tang, Kam Ki & Yazbeck, Myra, 2023. "Spillover effects of retirement: Does health vulnerability matter?," Economics & Human Biology, Elsevier, vol. 48(C).
    5. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
    6. Milan Ščasný & Emanuele Massetti & Jan Melichar & Samuel Carrara, 2015. "Quantifying the Ancillary Benefits of the Representative Concentration Pathways on Air Quality in Europe," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 62(2), pages 383-415, October.
    7. Anna Alberini, 2017. "Measuring the economic value of the effects of chemicals on ecological systems and human health," OECD Environment Working Papers 116, OECD Publishing.
    8. Jan-Walter De Neve & Rija L Andriantavison & Kevin Croke & Johannes Krisam & Voahirana H Rajoela & Rary A Rakotoarivony & Valérie Rambeloson & Linda Schultz & Jumana Qamruddin & Stéphane Verguet, 2018. "Health, financial, and education gains of investing in preventive chemotherapy for schistosomiasis, soil-transmitted helminthiases, and lymphatic filariasis in Madagascar: A modeling study," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 12(12), pages 1-17, December.
    9. Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin, 2020. "Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach," PharmacoEconomics, Springer, vol. 38(12), pages 1319-1331, December.
    10. Vosough, Shaghayegh & de Palma, André & Lindsey, Robin, 2022. "Pricing vehicle emissions and congestion externalities using a dynamic traffic network simulator," Transportation Research Part A: Policy and Practice, Elsevier, vol. 161(C), pages 1-24.
    11. Morton, Alec & Arulselvan, Ashwin & Thomas, Ranjeeta, 2018. "Allocation rules for global donors," LSE Research Online Documents on Economics 101210, London School of Economics and Political Science, LSE Library.
    12. Gerardo Sanchez Martinez & Joseph V. Spadaro & Dimitris Chapizanis & Vladimir Kendrovski & Mihail Kochubovski & Pierpaolo Mudu, 2018. "Health Impacts and Economic Costs of Air Pollution in the Metropolitan Area of Skopje," IJERPH, MDPI, vol. 15(4), pages 1-11, March.
    13. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
    14. Anuj Tiwari & David J Blok & Mohammad Arif & Jan Hendrik Richardus, 2020. "Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(8), pages 1-12, August.
    15. Morton, Alec & Arulselvan, Ashwin & Thomas, Ranjeeta, 2018. "Allocation rules for global donors," Journal of Health Economics, Elsevier, vol. 58(C), pages 67-75.
    16. Fattahi, Mohammad & Govindan, Kannan, 2018. "A multi-stage stochastic program for the sustainable design of biofuel supply chain networks under biomass supply uncertainty and disruption risk: A real-life case study," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 118(C), pages 534-567.
    17. Culyer, Anthony J., 2016. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Health Economics, Policy and Law, Cambridge University Press, vol. 11(4), pages 415-432, October.
    18. Laia Cirera & Beatriz Galatas & Sergi Alonso & Krijn Paaijmans & Miler Mamuquele & Helena Martí-Soler & Caterina Guinovart & Humberto Munguambe & Fabião Luis & Hoticha Nhantumbo & Júlia Montañà & Quiq, 2020. "Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-17, July.
    19. Amani Mori & Ole Norheim & Bjarne Robberstad, 2016. "Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania," PharmacoEconomics, Springer, vol. 34(3), pages 303-314, March.
    20. Marwân-al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo, 2021. "Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)," PharmacoEconomics, Springer, vol. 39(3), pages 331-343, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-02464775. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.